IDH1 and fibrosarcoma: We pursued an in vivo method for generating IDH-mutant tumors with acquired PARPi resistance: serial xenograft tumor studies utilizing HT1080 cells, a fibrosarcoma line carrying an endogenous IDH1 R132C/+ mutation (see schematic in Fig. 1A).